GlobeNewsWire
05 Jul 2026, 11:43 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ADMA Biologics is facing a securities class action lawsuit alleging the use of channel stuffing to artificially inflate revenue. — Allegations of revenue manipulation (channel stuffing) directly attack the integrity of financial statements and usually trigger significant sell-offs.
-0.60The lawsuit claims ADMA Biologics engaged in undisclosed related party transactions and lacked adequate internal controls. — Poor internal controls and undisclosed related party transactions suggest governance failures and potential for further accounting surprises.
-0.40The lead plaintiff deadline for the ADMA Biologics class action is August 10, 2026. — While a procedural milestone, it serves as a reminder of the ongoing legal risk and potential for future financial settlements.
-0.10Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is mentioned in the context of a securities class action notice from the Rosen Law Firm.
The company is facing a securities class action lawsuit alleging channel stuffing, undisclosed related party transactions, and lack of internal controls.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
27m ago
